1000802-34-5

Usage

Uses

Used in Pharmaceutical Research:
1,3-Benzodioxol-5-amine, 6-iodois used as a research compound for exploring its potential therapeutic effects on mental health conditions such as anxiety, depression, and PTSD. Its action as a releasing agent for neurotransmitters like serotonin, norepinephrine, and dopamine is of particular interest in understanding its impact on mood and emotional regulation.
Used in Therapeutic Applications:
In the field of therapy, 1,3-Benzodioxol-5-amine, 6-iodois being studied for its potential use as a treatment option for individuals suffering from anxiety, depression, and PTSD. 1,3-Benzodioxol-5-amine, 6-iodo-'s ability to induce feelings of euphoria, increased empathy, and emotional openness may contribute to its therapeutic value in these areas.
Used in Neurotransmitter Research:
1,3-Benzodioxol-5-amine, 6-iodois utilized in neuroscience research to investigate the role of serotonin, norepinephrine, and dopamine in mood regulation and mental health. Understanding how 1,3-Benzodioxol-5-amine, 6-iodo- interacts with these neurotransmitters can provide insights into the development of new treatments for various mental health disorders.
Used in Stimulant Effects Studies:
The stimulating effects of 1,3-Benzodioxol-5-amine, 6-iodo-, including heightened energy, focus, and sociability, make it a subject of interest in studies examining the mechanisms behind stimulant-induced effects on cognitive function and social behavior.

Upstream product

• 1000802-33-4 N-(6-iodobenzo[d][1,3]dioxol-5-yl)acetamide 
• 13067-19-1 3,4-methylenedioxyacetanilide 
• 14268-66-7 benzo[1,3]dioxolo-5-ylamine 

Downstream Products

• 106517-64-0 5,6-methylenedioxyindolyl-2-carboxylic acid 

Relevant academic research and scientific papers

Chelating Group Enabled Palladium-Catalyzed Regiodivergent Carbonylative Synthesis of 2,3-Dihydroquinolin-4(1H)-ones

A new procedure on palladium-catalyzed carbonylative cyclization of N-(2-pyridyl)sulfonyl (N-SO2Py)-2-iodoanilines with terminal alkenes has been developed for the rapid construction of dihydroquinolin-4(1H)-one scaffolds. Enabled by the chelat

Fused Amino Pyridines for the Treatment of Lung Cancer

The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94

Grp94 is involved in the regulation of a restricted number of proteins and represents a potential target in a host of diseases, including cancer, septic shock, autoimmune diseases, chronic inflammatory conditions, diabetes, coronary thrombosis, and stroke. We have recently identified a novel allosteric pocket located in the Grp94 N-terminal binding site that can be used to design ligands with a 2-log selectivity over the other Hsp90 paralogs. Here we perform extensive SAR investigations in this ligand series and rationalize the affinity and paralog selectivity of choice derivatives by molecular modeling. We then use this to design 18c, a derivative with good potency for Grp94 (IC50 = 0.22 μM) and selectivity over other paralogs (>100- and 33-fold for Hsp90α/β and Trap-1, respectively). The paralog selectivity and target-mediated activity of 18c was confirmed in cells through several functional readouts. Compound 18c was also inert when tested against a large panel of kinases. We show that 18c has biological activity in several cellular models of inflammation and cancer and also present here for the first time the in vivo profile of a Grp94 inhibitor.

HSP90 INHIBITORS

The disclosure relates to Compounds of Formulae (IA) and (IB), and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Xd, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (IA) and/or (IB), and methods to treat or prevent a condition, such cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (IA) or (IB). The disclosure further relates to compounds of Formulae (IA) and (IB) in which X2 is a leaving for introducing a radiolabeled atom, such as 124I or 131I and to methods of using such compounds in the preparation of radiolabeled compounds, particularly for use in imaging.

FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS

The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.

FUSED AMINO PYRIDINE AS HSP90 INHIBITORS

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of thiazole derivatives which are substituted in the 2-position by a substituted morpholin-4-yl moiety, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.